Pharmaceutical Executive February 12, 2024
Takeda expects Eohilia single-dose stick packs will be available by the end of February for patients aged 11 years and older with eosinophilic esophagitis.
The FDA has approved Takeda’s Eohilia (budesonide oral suspension) for the treatment of patients aged 11 years and older with eosinophilic esophagitis (EoE). The regulatory action makes Eohilia the first and only approved oral treatment for this patient population, with Takeda stating it expects Eohilia 2 mg/10 mL single-dose stick packs to be available by the end of February.1
“Various formulations of corticosteroids have been used in the past to manage EoE, but in an off-label capacity and using multiple delivery options. With Eohilia, it’s gratifying to...
Today's Sponsors
Today's Sponsor